These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26081252)

  • 41. Prevention of gastrointestinal side-effects in paediatric oncology: what are the guidelines?
    Cheng KKF
    Curr Opin Support Palliat Care; 2017 Jun; 11(2):120-124. PubMed ID: 28333866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
    Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
    Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
    Hayashi T; Ikesue H; Esaki T; Fukazawa M; Abe M; Ohno S; Tomizawa T; Oishi R
    Support Care Cancer; 2012 Aug; 20(8):1805-10. PubMed ID: 21947491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
    Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
    Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting.
    Todaro B
    J Natl Compr Canc Netw; 2012 Apr; 10(4):487-92. PubMed ID: 22491047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. International patterns of practice in the management of radiation therapy-induced nausea and vomiting.
    Dennis K; Zhang L; Lutz S; van Baardwijk A; van der Linden Y; Holt T; Arnalot PF; Lagrange JL; Maranzano E; Liu R; Wong KH; Wong LC; Vassiliou V; Corn BW; De Angelis C; Holden L; Wong CS; Chow E
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):e49-60. PubMed ID: 22704982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement.
    Einhorn LH; Rapoport B; Koeller J; Grunberg SM; Feyer P; Rittenberg C; Aapro M
    Support Care Cancer; 2005 Feb; 13(2):112-6. PubMed ID: 15480812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
    Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [New developments in the treatment of nausea and vomiting caused by chemotherapy].
    de Wit R; van Alphen MM
    Ned Tijdschr Geneeskd; 2003 Apr; 147(15):690-4. PubMed ID: 12722531
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics.
    Perwitasari DA; Gelderblom H; Atthobari J; Mustofa M; Dwiprahasto I; Nortier JW; Guchelaar HJ
    Int J Clin Pharm; 2011 Feb; 33(1):33-43. PubMed ID: 21365391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk.
    Fujii H; Iihara H; Ishihara M; Takahashi T; Yoshida K; Itoh Y
    Anticancer Res; 2013 Dec; 33(12):5549-56. PubMed ID: 24324096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
    Herrstedt J
    Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
    Navari RM; Aapro M
    N Engl J Med; 2016 Apr; 374(14):1356-67. PubMed ID: 27050207
    [No Abstract]   [Full Text] [Related]  

  • 55. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group.
    Araz M; Karaagac M; Korkmaz L; Beypinar I; Uysal M
    Curr Probl Cancer; 2019 Aug; 43(4):344-353. PubMed ID: 30497851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
    Ellebaek E; Herrstedt J
    Curr Opin Support Palliat Care; 2008 Mar; 2(1):28-34. PubMed ID: 18685391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Chemotherapy induced emesis: pathophysiology and prevention].
    Mailliez A; Bonneterre J
    Bull Cancer; 2010 Feb; 97(2):233-43. PubMed ID: 20051348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan.
    Okuyama A; Nakamura F; Higashi T
    Support Care Cancer; 2014 Jul; 22(7):1789-95. PubMed ID: 24522743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement.
    Einhorn LH; Grunberg SM; Rapoport B; Rittenberg C; Feyer P
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S1-4. PubMed ID: 20505956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.